Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/17055
Title: Personalized chemosensitivity assays for mesothelioma- is it worth the effort?
Austin Authors: John, Thomas ;Chia, Puey Ling 
Affiliation: Medical Oncology, Olivia Newton-John Cancer Research Institute
Medical Oncology, University of Melbourne, Olivia Newton-John Cancer Research Institute.
Issue Date: 19-Jan-2018
metadata.dc.date: 2018
Publication information: Clinical Cancer Research 2018; online first: 19 January
Abstract: Cell-lines formed from an individual's tumor can be used to predict response to specific therapies and determine genomic predictors. For mesothelioma, where chemotherapy remains the backbone of current therapeutic paradigms, such assays could be used to treat patients with the most effective agents specific to their "chemical profile".
URI: http://ahro.austin.org.au/austinjspui/handle/1/17055
DOI: 10.1158/1078-0432.CCR-17-3493
PubMed URL: 29351918
PubMed URL: https://pubmed.ncbi.nlm.nih.gov/29351918
ISSN: 1078-0432
Type: Journal Article
Appears in Collections:Journal articles

Show full item record

Page view(s)

2
checked on Dec 2, 2022

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.